Rajat Bhasker currently serves as the Project and Process Engineering Lead at Novartis, where he leverages his extensive expertise in pharmaceutical manufacturing and engineering design to drive innovation and efficiency across multiple projects. With a robust background in technology transfer and capital expenditure (CAPEX) management,...
Rajat Bhasker currently serves as the Project and Process Engineering Lead at Novartis, where he leverages his extensive expertise in pharmaceutical manufacturing and engineering design to drive innovation and efficiency across multiple projects. With a robust background in technology transfer and capital expenditure (CAPEX) management, Rajat plays a pivotal role in overseeing the Singapore sites' CAPEX initiatives, ensuring that projects not only meet regulatory standards but also align with the strategic goals of the organization. His leadership in managing the pharmaceutical process design team has been instrumental in executing projects valued at up to USD 5 million, showcasing his ability to navigate complex project landscapes while maintaining a focus on quality and compliance.
Rajat's proficiency extends to critical areas such as cleaning validation, cleaning verification, and the management of clean-in-place (CIP) and steam-in-place (SIP) processes. His comprehensive understanding of clean utility systems, including water for injection (WFI) and clean steam design, positions him as a key contributor to the development of safe and efficient pharmaceutical manufacturing environments. Additionally, Rajat is adept at managing document management systems, ensuring that all project documentation adheres to stringent industry standards and facilitates seamless communication among stakeholders.
His skill set is further enhanced by his experience in business development and energy audits, allowing him to identify opportunities for process optimization and sustainability within the pharmaceutical sector. Rajat’s commitment to process safety and change control underscores his dedication to fostering a culture of continuous improvement, making him an invaluable asset to Novartis and the broader pharmaceutical industry.
